The interruption of angiogenesis using herbal extracts is now recognized as a useful approach for treating many solid tumors. To date, the best-validated antitumor approach is to target the vascular endothelial growth factor (VEGF)-induced angiogenic pathway. In the present study, we first identified the antiangiogenic activity of a hot-water extract of Rubus coreanus Miquel (RCMHE) in vitro and ex vivo. This extract suppressed VEGF-induced angiogenesis, the phosphorylation of extracellular regulated kinase (ERK), p38 and the activation of matrix metalloproteinases (MMPs). RCMHE also inhibited the VEGF-responsive phosphorylation of VEGFR2. These results clearly show that RCMHE may have potential therapeutic value for angiogenesis-associated human diseases through the suppression of angiogenesis and the interruption of the phosphorylation of VEGFR2.
Introduction
Many natural products have a long history of use as alternative remedies for a variety of tumors with relatively few side effects [8, 20, 27, 42, 58] . Korean black raspberry, a fruit of Rubus coreanus Miquel (RCM), has been used as a traditional herbal medicine for the treatment of prostate symptoms, diabetes mellitus, impotence, spermatorrhea, enuresis, and asthma [29, 38, 39, 48] . RCM extract has been reported to have antioxidant [27] , anti-inflammatory [10, 38] , and anti-cancer activities [25, 31] . Even though numerous biological activities of RCM have been reported, there is no evidence regarding extract's effect on angiogenesis and its underlying mechanisms.
Angiogenesis, the formation of new blood vessels from pre-existing ones, is an essential step for physiological processes such as wound healing, reproduction, and embryonic development [18] , and also plays important roles in many pathological processes such as tumor growth and metastasis [11, 14] . VEGF, the most effective biological inducer of angiogenesis, is up-regulated and serves as a major angiogenic factor in the vascular development of tumors [30, 53] . Without an adequate blood supply, the tumor cannot grow larger than 1-2 mm in diameter [12] . A variety of approaches to block VEGF signaling are currently being assessed in preclinical and clinical trials [15, 23, 45] , but the chronic therapeutic use of these anti-VEGF agents is limited due to side effects [28] . Therefore, anti-angiogenic therapy using natural compounds with fewer side effects is a promising strategy for tumor treatment. Recently, several plant-derived compounds have been shown to be potent inhibitors of angiogenesis [6, 9, 33, 34, 52, 54, 60] .
In the present study, we found for the first time that the natural compound hot-water extract of Rubus coreanus Miquel (RCMHE) suppresses VEGF-induced angiogenesis by inhibiting proliferation, migration, invasion, tube formation, and vessel sprouting in vitro and ex vivo. Furthermore, we found that the VEGF-stimulated phosphorylation of ERK, p38 and VEGFR2, as well as the expression of matrix metalloproteinases (MMPs) were inhibited by RCMHE treatment. These results indicate that RCMHE is a potent anti-angiogenic drug candidate for the treatment of angiogenesis-related diseases such as tumors and diabetic retinopathy.
Materials and methods

Preparation of Rubus coreanus Miquel hot-water extract
RCM was harvested at 2012 in Kochang (GPS : E 126° 39´ N 41° 33´) and Jungeup (GPS : E 126° 58´ N 47° 66´). For the sample preparation, 400 g of the dried RCM was extracted three times with 2 l of water at 100°C for one day, and then filtered with Whatman No. 1 paper, combined, and concentrated using a rotary evaporator (EYELA N-1000, Japan) at 40°C. Finally, the dried RCMHE was obtained.
RCMHE was stored in a cold chamber of Lab. of Molecular Pharmacogenomics, Yonsei University at 4°C and relative humidity at 25~30%. 
Endothelial cell viability assay
Cell viability was evaluated using the MTT colorimetric assay. HUVECs (5×10 4 cells) were first plated in gelatinized 24-well plates and cultured overnight. Cells were then treated with 1-100 μg/ml RCMHE for 24 hr. At the end of the treatment, 100 μl of the MTT (5 mg/ml) was added to each well. After 4 hr, the residual MTT was carefully removed, and the crystals were dissolved by incubation with DMSO for 30 min. The plates were then shaken for 5 min, and the absorbance at 595 nm was measured using a microplate reader (Molecular Devices, Sunnyvale, CA, USA). The cell viability was calculated as follows: cell viability (%) = (average absorbance of the RCMHE-containing serum group/average absorbance of the blank group) ×100.
Endothelial cell proliferation assay
We determined the effects of RCMHE on the pro- Cell counter (Logos Biosystems, Korea).
Western blot analysis
Cells were harvested and lysed with RIPA buffer containing 2 mM EDTA, 137 mM NaCl, 20 mM Tris-HCl (pH 8.0), 1 mM Na3VO4, 10 mM NaF, 1 mM PMSF, 1% Triton X-100, 10% glycerol, and a protease-inhibitor cocktail. The lysates were resolved by electrophoresis on sodium dodecyl sulfate-polyacrylamide gels electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride membranes (Pall Corporation, East Hills, NY, USA). The blotted membranes were then incubated with the indicated antibodies and the immunoreactive bands were visualized using a chemiluminescent substrate.
Endothelial cell migration assay
In vitro cell migration was assessed using a modified
Boyden chamber assay, as described previously [51] .
Transwells ( 
Endothelial cell invasion assay
Endothelial cell invasion assay was assessed using a 
Gelatinolytic zymography
To detect the expression of MMPs in response to VEGF in supernatant media in the presence or absence of RCMHE, we used the zymogram assay, as described previously [35] . Briefly, collected medium was centrifuged at 1,500 rpm for 5 min at 4°C to remove cellular debris. The conditioned media containing 20 μg of secreted proteins was then mixed with SDS-PAGE loading buffer without a reducing agent. Cultured media samples were then electrophoresed onto 10% SDS-PAGE copolymerized with 0.2% gelatin. Gels were washed twice for 30 min with 2.5%
Triton X-100 solution, rinsed with incubation buffer (50 mM
Tris-HCl buffer, pH 7.5 containing 10 mM CaCl2, plus 1 μM ZnCl2) and then incubated at 37°C for either 3 hr or 12 hr. MMP-2 and MMP-9 were identified following the staining of the gel in 0.25% Coomassie Brilliant Blue R250 (Sigma) and the de-staining in 7% acetic acid.
In vitro capillary-like tube formation assay This experiment examined endothelial tube formation using a tubular morphogenesis assay. Matrigel basement membrane matrix was used as a substrate for the in vitro study of angiogenesis [36] . Briefly, 250 μl of growth fac- 
Ex vivo rat aortic sprouting assay
The three-dimensional rat aortic ring sprouting assay was used as a model for the ex vivo angiogenesis study [3] .
Briefly, a 48-well plate was first covered with Matrigel (120 μl) and incubated for 30 min at 37°C. Subsequently, the dorsal aortas from the sacrificed Sprague-Dawley rats were dissected and cut into 1 mm long pieces using a sterile surgical blade. Afterwards, the aortic rings were placed into wells pre-coated with Matrigel and then covered with another layer of Matrigel (50 μl). After polymerization for 30 min, VEGF with or without RCMHE was then added to each well in a final volume of 600 μl of human endothelial serum-free M199 media. On day 7, the rings were photographed using a Nikon eclipse TS100 inverted microscope and the sprouted neovessels were quantified. Sprouting was measured using the following scale: 0 = no sprouting; 
Statistical analysis
The results are presented as means ± standard deviations (SDs). Statistical analysis of the data was performed using the Student's t-test and one-way analysis of variance (ANOVA). p<0.05 was considered statistically significant.
Results
Effect of RCMHE on the viability of vascular endothelial cells
We first examined the viability of HUVECs after exposure to RCMHE. Treatment with various concentrations of RCMHE for 24 hr induced cytotoxicity in a dose-dependent manner (Fig. 1A) . A significant inhibitory effect on cell viability was observed in response to RCMHE at concentrations ≥50 μg/ml. No significant cytotoxicity was observed at doses of up to 25 μg/ml RCMHE during the 24 hr cultivation period.
RCMHE treatment inhibits VEGF-induced endothelial cell proliferation
We next examined the effect of RCMHE on VEGF-induced endothelial cell proliferation by employing a cell counting assay. Proliferation of the endothelial cells in response to an angiogenic factor is an important step during angiogenesis. HUVECs were pretreated for 40 min with various concentrations of RCMHE (1-25 μg/ml) before being exposed to VEGF (20 ng/ml) for 24 hr. RCMHE inhibited VEGF-induced proliferation, with half maximal inhibition taking place at 5 μg/ml (Fig. 1B) . These inhibitory effects were not due to cytotoxicity because RCMHE up to 25 μg/ml had no effect on the normal growth of HUVECs in the absence of VEGF (Fig. 1A) .
RCMHE inhibits ERK, p38, and VEGFR2 phosphorylation by VEGF
In order to identify the downstream signaling pathways targeted by RCMHE, we examined the phosphorylation of ERK and p38 MAPKs, the important key signaling pathways that drive endothelial cell proliferation, migration and tube formation. The VEGF-induced phosphorylation of ERK and p38 was inhibited by RCMHE in a dose-responsive manner ( Fig. 2A and B) . Next, to evaluate the possibility that the anti-angiogenic effects of RCMHE were mediated through the inhibition of VEGFR2 phosphorylation, we also performed Western blot analysis. We found that RCMHE treatment inhibited the VEGF-induced phosphorylation of VEGFR2, but VEGFR2 expression was not affected by RCMHE treatment itself (Fig. 2C) .
RCMHE reduces VEGF-induced endothelial cell migration
Because the migration of endothelial cells is essential for tumor angiogenesis, we next examined the ability of Fig. 2 . Effect of RCMHE on the phosphorylation of ERK, p38 and VEGFR2 induced by VEGF. HUVECs were incubated for 40 min with various concentrations (1, 5, 10, and 25 μg/ml) of RCMHE, followed by VEGF stimulation (20 ng/ml) for 10 min. Next, cells were harvested and the levels of phosphorylated and total ERK (A), p38 (B) and VEGFR2 (C) were determined by Western blot analysis. Densitometric quantification of the Western blot data is expressed as the mean ± SD (n = 3). **p<0.01 versus VEGF alone. Fig. 3 . Effect of RCMHE on VEGF-induced endothelial cell motility. HUVECs were pretreated for 40 min with various concentrations (1, 5, 10, and 25 μg/ml) of RCMHE before exposure to VEGF (20 ng/ml). After incubation for 4 hr, chemotactic migration was evaluated. Cells that migrated to the bottom of the filter were photographed (A) and counted (B) using optical microscopy. An in vitro migration assay was performed as described in the Materials and methods section. Data are expressed as the mean ± SD from triplicate experiments. **p<0.01 versus VEGF alone.
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RCMHE to inhibit cell motility in migration assays. In the absence of RCMHE, a large number of endothelial cells migrated to the lower side of the filter in the Transwell
Chamber following stimulation with 20 ng/ml VEGF. This VEGF-induced migration of HUVECs was significantly reduced by RCMHE treatment in a dose-dependent manner (Fig. 3) . However, RCMHE alone had no significant effect on the basal migration of endothelial cells.
RCMHE inhibits endothelial cell invasion and MMP expression in response to VEGF
Next, we evaluated the ability of RCMHE to inhibit the invasion of human endothelial cells using a Transwell culture plate. The number of invading cells in response to VEGF was significantly reduced in a dose-dependent manner by RCMHE treatment (Fig. 4A ). The VEGF-stimulated activation of MMP-2 and -9 was inhibited by RCMHE treatment (Fig. 4B ). In addition, we used conditioned medium with PMA-stimulated HUVECs to distinguish between different MMPs [22] .
RCMHE treatment suppresses the VEGF-stimulated tube formation of HUVECs
To characterize the anti-angiogenic activity of RCMHE, we examined its ability to inhibit VEGF-induced tube formation by endothelial cells on Matrigel, a well-known angiogenesis assay. HUVECs exposed to VEGF for 20 hr showed extensive and robust tube-like structures with increasing numbers of branch points. By contrast, RCMHE treatment dose-dependently reduced both the width and length of the endothelial tubes induced by VEGF (Fig. 5) .
RCMHE inhibits VEGF-stimulated vessel sprouting ex vivo
To further verify the anti-angiogenic effect of RCMHE ex vivo, we employed the rat aortic ring sprouting assay [44] , a widely used ex vivo anti-angiogenesis assay in which growing microvessels undergo many key features of angiogenesis over a timescale similar to that observed in vivo. Rat aortic rings were embedded in Matrigel and fed with medium containing different concentrations of RCMHE. Next, the rings were stimulated with 20 ng/ml VEGF and the subsequent sprouting was examined by inverted microscopy. VEGF significantly stimulated vessel outgrowth when compared to the results with medium alone.
However, RCMHE treatment dramatically reduced the sprout length and density induced by VEGF (Fig. 6 ).
Discussion
VEGF, the most important angiogenic factor in tumor growth and metastasis, has emerged as an attractive target for anti-angiogenesis treatment [16, 21] . Many anti-angio- to serious side effects [28] . Therefore, there has been a renewed interest in identifying VEGF inhibitors from natural herbal sources, given the advantage of their proven safety for human use [5, 7, 13] . Additionally, certain plant-derived diets containing phytochemicals have been implicated in the prevention of cancer development and progression [2, 24, 50, 56] . The fruit of the black raspberry, RCM, was reported to have anti-inflammatory, anti-nociceptive, anti-gastropathic, anti-rheumatic, and chemopreventive effects [12, 31, 40] . However, the anti-angiogenic properties of RCMHE and its underlying mechanisms have not been studied. This study is the first to identify the anti-angiogenic activity of RCMHE using both in vitro and ex vivo models.
The binding of VEGF to KDR/VEGFR2, a primary mediator of VEGF signaling [19] , results in the phosphorylation of VEGFR2, which in turn transmit signals to various intra-cellular proteins such as p44/42 MAPK (ERK1/2) and p38 MAPK. This cascade promotes survival, induces proliferation, enhances migration and invasion, and results in tube formation in the endothelial cells, which contribute to vascular sprouting in the tumor [37, 46, 47, 51] . In the present study, we observed that RCMHE significantly suppressed the stimulatory effect of VEGF on endothelial cell proliferation (Fig. 1B) , and reduced the migration and tube area of the endothelial tubes induced by VEGF (Fig. 3 and   Fig. 5 ). Since RCMHE had no significant effect on the normal growth of endothelial cells up to concentrations of 25 μg/ml (Fig. 1A) , its anti-proliferative action at low concentrations seems to reflect a specific response to the endothelial cells stimulated by VEGF. Recently, we reported that cold-water extracts of Rubus coreanus Miquel (RCME) inhibited angiogenesis in vitro and ex vivo (in press).
To clarify the anti-angiogenic signaling mechanisms of RCMHE, we examined its effect on the activation of ERK, [43] and are up-regulated by VEGF [49, 59] . Selective inhibitors of MMP-2 and MMP-9 have been shown to block tumor and endothelial cell migration in vitro and tumor growth and invasion in vivo [32] . However, the relationship between MMPs and angiogenesis is much more complicated. In this experiment, we observed that RCMHE markedly reduces the number of invaded endothelial cells and the activation of MMP-2 and MMP-9 (Fig. 4) .
Similarly, RCMHE strongly suppressed the sprouting of endothelial cells in the rat aorta in response to VEGF (Fig. 6 ).
This ex vivo anti-angiogenic activity of RCMHE may be explained by its inhibitory effect on the proliferation, migration, invasion, and tube formation of endothelial cells in response to VEGF through the inhibition of the tyrosine phosphorylation of VEGFR2.
In conclusion, our present study demonstrated for the first time that RCMHE inhibits VEGF-induced angiogenesis in vitro and ex vivo. Our results not only provide additional pharmacological information regarding the therapeutic efficacy of RCM, but also show its potential as a novel candidate for the development of new pharmaceutical anti-angiogenic drugs targeting the VEGF signaling pathway.
